QRX003
Phase 1- Indications
- Netherton Syndrome
Company intelligence / Profile preview
Skinvisible Pharmaceuticals, Inc.
Las Vegas/Henderson, Nevada, United Statesskinvisible.com ↗
- Ownership
- Public · SKVI
- Development stage
- Phase 1
01
Overview
Skinvisible has developed over 40 proprietary topical/transdermal products using its patented Invisicare® platform. Its lead outlicensed candidate QRX003 for Netherton syndrome has reached Phase 2/3 clinical trials with a licensee and shows promise as a novel serine protease inhibitor formulation. The company recently filed a patent for transdermal obesity drugs using GLP‑1 agonists and CB‑1 antagonists delivered via Invisicare®, aiming to improve efficacy and patient compliance compared to oral/injectable therapies[5][7].
- Therapeutic areas
- OncologyEndocrinologyDermatologyInfectious Diseases
- Modalities
- Small moleculestopical and transdermal drug delivery systems
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Licensees include Quoin Pharmaceuticals for QRX003/Netherton Syndrome program[7].Other partnerships with pharmaceutical/cosmetic companies seeking new or enhanced topical products through licensing model[6].
04
Financials
- Market cap
- $1.1M
- Total revenue
- $5K
- Enterprise value
- $6.8M
Beyond the preview
Go deeper on Skinvisible Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Skinvisible Pharmaceuticals, Inc..